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Abstract
Background: The 12-item Health Survey (SF-12) was developed as a shorter alternative to the
SF-36 for use in large-scale studies, particularly when overall physical and mental health are the
outcomes of interest instead of the typical eight-scale profile. The main purpose of this study was
to assess the validity of the Greek version of the SF-12.
Methods: A stratified representative sample (N = 1005) of the Greek general population was
interviewed. The survey included the SF-36, the EQ-5D and questions on socio-demographic and
health-related characteristics. SF-12 summary scores were derived using the standard US
algorithm. Factor analysis was used to confirm the hypothesized component structure of the SF-12
items. Construct validity was investigated with "known groups" validity testing and via convergent
and divergent validity, which in turn were assessed by the correlations with the EQ-5D dimensions.
Concurrent validity was assessed by comparisons with SF-36 summary scores.
Results: SF-12 summary scores distinguished well, and in the expected manner, between groups
of respondents on the basis of gender, age, education, socio-economic status, self-reported health
problems and health services utilization, thus providing evidence of construct validity. Effect size
differences between SF-36 and SF-12 summary scores were generally small (<0.2), supporting
concurrent (criterion) validity. Significantly lower mean PCS-12 and MCS-12 scores were observed
for respondents reporting chronic conditions compared to those without (P < 0.001). Convergent
and divergent validity were supported by expected relationships with the EQ-5D. Reporting a
problem in an EQ dimension was associated with lower SF-12 summary scores, supporting
concurrent validity. Sensitivity of the Greek SF-12 and replication of the original measurement and
conceptual model were demonstrated.
Conclusion: The results provide evidence on the validity of the Greek SF-12 and, in conjunction
to future studies addressing test-retest reliability and responsiveness, support its use in Greek
health status studies as a brief, yet valid, alternative to the SF-36.
Background
In medical research and evaluation, there is an increasing
interest in instruments used to measure health-related
quality of life (HRQOL) in general population surveys, as
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well as across a variety of diseases and conditions.
HRQOL is a multidimensional concept that includes
physical, psychological and social domains of health and
is generally accepted as an important outcome measure of
health care [1]. The two main approaches to measuring
HRQOL are generic and disease-specific instruments, and
the majority of experts recommend the use of both con-
currently [2]. Regarding the generic instruments, the Short
Form Health Survey (SF-36) is probably the one that is
most widely used [3].
The SF-36 includes eight dimensions: physical function-
ing (PF), role physical (RP), bodily pain (BP), general
health (GH), vitality (VT), social functioning (SF), role
emotional (RE), and mental health (MH) [4]. Each
dimension is scored on a 0–100 scale with 0 and 100 cor-
responding to worst and best HRQOL respectively [5],
and the eight dimensions can be summarized in two sum-
mary scores of physical and mental health [6], hereinafter
referred to as PCS-36 and MCS-36.
The 12-item Health Survey (SF-12) was developed as a
shorter alternative to the SF-36 for use in large-scale stud-
ies, and its reliability and validity have been documented
[7]. Scale scores are estimated for four of the health con-
cepts (PF, RP, RE and MH) using two items each, whereas
the remaining four (BP, GH, VT and SF) are represented
by a single item. All 12 items are used to calculate the
physical and mental component summary scores (PCS-12
and MCS-12) by applying a scoring algorithm empirically
derived from the data of a US general population survey
[8]. Performance of the component summary scores was
initially studied in nine languages and it has been recom-
mended that the US-derived summary scores, which yield
a mean of 50 and a SD of 10, be used in order to facilitate
cross-cultural comparison of results [9].
The SF-12 has been extensively used in health status stud-
ies involving the general population [10-12], as well as in
studies with disease groups [13-16]. As for the SF-36, it
has been translated into Greek and its reliability and
validity were established in a sample of 1007 adults living
in the greater Athens area. It was found to have high inter-
nal consistency reliability, convergent and discriminative
validity and able to distinguish between groups of
respondents in the expected manner (known-groups
validity) on the basis of gender, age and socio-economic
status [17]. Using the same sample, the eight-scale struc-
ture of the Greek version of the instrument has been con-
firmed as well [18].
Recently, the SF-12 (embedded within the SF-36) was
administered to a nationally representative sample in a
large-scale study aiming to assess the health of the Greek
population. The aim of the present study was to examine
the psychometric properties of the SF-12 summary scores
in terms of the measurement and conceptual model, sen-
sitivity, "known groups" construct validity, convergent
and divergent validity and concurrent (criterion) validity
and, hence, to increase confidence in using the SF-12 in
Greek studies as an alternative to the more time-demand-
ing SF-36.
Methods
Sample and data collection
The study was conducted in September 2006 and involved
a sample (>18 years old) residing in urban (>2,000 inhab-
itants) and rural (<2,000 inhabitants) areas of the country
and in each of the 13 geographical regions. According to
the latest Population Census (2001), the survey popula-
tion consisted of 8,880,924 individuals. Non-fluent Greek
speakers, institutionalized subjects and those incapable of
reasoning and decision-making on their own were
excluded. Participants were grouped, proportionally to
the Greek population, by socio-demographic characteris-
tics according to a three-staged sampling methodology. In
the first stage, a random sample of building blocks was
selected proportionally to size. In the second, households
were randomly selected by systematic sampling. In the
third stage an eligible participant was selected by simple
random sampling in each household. In total 1,005 will-
ing subjects, out of 1,388 initially approached (response
rate 72.4%), agreed to participate and were interviewed
face-to-face by trained interviewers. The Research Com-
mittee of the Hellenic Open University ethically approved
the study and all subjects provided informed consent.
Survey
Two HRQOL instruments, the SF-36 and the EuroQol EQ-
5D, were included in the study. The latter is a two-part,
preference-based HRQOL measure, developed by a multi-
disciplinary transnational consortium of investigators
[19]. It addresses five domains: mobility, self-care, usual
activities, pain/discomfort and anxiety/depression, with
each divided into three severity levels. The second part
consists of a vertical 0–100 visual analogue scale (VAS).
The EQ-5D has been translated into most major lan-
guages, including Greek, and initial evidence on its appli-
cability and adaptability to the Greek environment has
been provided [20]. Currently, a large-scale general popu-
lation study is in progress aiming to demonstrate the con-
struct validity of the Greek version of the instrument.
Subjects reported information on socio-demographic var-
iables such as gender, age, marital status, education and
employment, with the latter two serving as proxy-estima-
tors of socio-economic status, as information on income
could not be reliably collected. Data were also collected
regarding various clinical conditions, which are known to
be reliable when self reported [21,22]. Utilization of
health services such as past-month physician consulta-Health and Quality of Life Outcomes 2007, 5:55 http://www.hqlo.com/content/5/1/55
Page 3 of 9
(page number not for citation purposes)
tions and past-year hospital admissions were also
recorded, as they have been shown to be associated with
HRQOL [23,24].
Psychometric properties
The sensitivity of the SF-12 measurement model was eval-
uated by examining: i) response distributions for each
item in order to ensure that the full range of possible
responses is used and ii) summary floor and ceiling effects
to assess the ability of the items to capture the full range
of health states. To ensure that the original conceptual
model is satisfactorily replicated, principal components
factor analysis with varimax rotation was used, a proce-
dure previously performed in similar studies [13,25]. It
was hypothesized that two factors would be obtained. In
addition, items originally belonging to the PF, RP, BP and
GH domains were hypothesized to load higher on the
physical health factor, whereas the VT, SF, RE and MH
items were hypothesized to load higher on the mental
health factor. However, it has been suggested that VT and
SF crossload on both physical and mental components [8]
and a crossloading of ≥0.40 is considered to be meaning-
ful [26].
Furthermore, the correlation between physical compo-
nent items and the PCS score should be higher than with
the MCS score and vice versa, i.e. the correlation between
mental component items and the MCS score should be
higher than with the PCS score [7]. These relationships
were examined for the SF-12 items. The proportion of the
total variance of PCS-36 and MCS-36 scores explained by
PCS-12 and MCS-12 scores respectively was used to assess
content validity and the expected standard was ≥90% [8].
This was further evaluated by Pearson's correlation coeffi-
cients between SF-12 and SF-36 PCS and MCS scores, and
the expected standard was ≥0.9 [8,9].
"Known groups" construct validity was assessed by exam-
ining hypothesized relationships between sociodemo-
graphic and health-related variables and SF-12
component scores. Specifically, it was expected that
females, older subjects, widowed or divorced persons,
those with less education and the unemployed would
report poorer health [10,11]. It was also expected that
those reporting greater use of health services and/or exist-
ing clinical conditions would have a lower HRQOL as
well [21-24]. Effect size differences between correspond-
ing SF-12 and SF-36 PCS and MCS scores were used to
determine if the SF-12 gave similar results to the SF-36
(criterion validity). The effect size difference between SF-
36 and SF-12 scores was calculated by dividing their dif-
ference by the standard deviation of the SF-36 summary
score. To assess the relative magnitude of change, it has
been suggested that an effect size of 0.2 is regarded as
small, 0.50 as moderate and 0.80 as large [27].
The ability of the SF-12 to discriminate between different
levels of health was determined by comparing mean sum-
mary scores for subjects reporting no problem, a moderate
problem or a serious problem for a given EQ-5D dimen-
sion, and it was expected that scores would be higher in
the first case [28]. Convergent and divergent validity of
the SF-12 were examined via the relationships with the
EQ-5D, and it was expected that comparable summary
scores and dimensions, e.g. PCS-12 with mobility, self-
care, usual activities and pain/discomfort and MCS-12
with anxiety/depression would correlate better, compared
to less comparable dimensions. Contrarily, the EQ VAS
should correlate reasonably well with both SF-12 sum-
mary scores [29].
Statistical analysis
Data were analyzed using SPSS ver. 13.0 (SPSS Inc., Chi-
cago IL). Summary scores, according to subgroups, were
compared with t-Test and ANOVA. Linear regression was
performed to determine the total variance of the PCS-36
and MCS-36 scores explained by the SF-12 items. Pear-
son's correlation coefficient (r) was used to measure the
association between SF-12 and SF-36 PCS and MCS scores
and between EQ dimensions and VAS with SF-12 sum-
mary scores. Correlations >0.50 were regarded as strong
[30]. For all tests, statistical significance was assumed for
P values <0.05.
Results
The SF-12 item and summary descriptive statistics are pre-
sented in Table 1. Four of the items were recoded so that
higher scores correspond to better health. Responses were
clustered at the upper end of the measurement scale, as
could have been expected in a general population. Despite
this, the full range of possible responses has been used sat-
isfactorily, supporting the overall sensitivity of the meas-
urement model. The PCS-12 and MCS-12 summary scores
were negatively skewed since respondents scored towards
the higher end of the health spectrum. However, no floor
or ceiling effects were observed, implying that the SF-12
items captured the full range of health states.
The two-factor conceptual structure of the SF-12 was con-
firmed (Table 2). Principal components analysis, after var-
imax rotation, showed that PF, RP, BP and GH items
loaded higher on the physical component, whereas RE
and MH items loaded higher on the mental component.
The VT and SF items expectedly loaded on both compo-
nents and similar results have been reported elsewhere
[7,13]. Correlations (Pearson's r) of individual items and
the SF-12 summary scores are also shown in Table 2.
Items comprising the PF, RP, BP and GH domains corre-
lated higher with the PCS score, whereas the SF, RE and
MH items correlated better the MCS score. These results
confirmed the hypothesized item-component correla-Health and Quality of Life Outcomes 2007, 5:55 http://www.hqlo.com/content/5/1/55
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tions, with one exception, namely the VT item appearing
to correlate slightly higher with the PCS score.
The PCS-12 and MCS-12 summary scores explained
93.2% and 86.9% of the total variance of the PCS-36 and
MCS-36 summary scores respectively (expected standard
90%), supporting content validity of the Greek SF-12. This
was further supported by the correlations between SF-36
and SF-12 summary scores exceeding the expected 0.9
standard. Specifically r = 0.97 (P < 0.01) between PCS-36
and PCS-12 and r = 0.93 (P < 0.01) between MCS-36 and
MCS-12. These high correlations are an indication of the
validity of the SF-12 scores, with the SF-36 scores acting as
criterion variables.
Table 2: Factor structure and item-component correlations of the SF-12
Factor structure correlations
Item description SF-12 domain Factor 1 Factor 2 PCS-12 MCS-12
Moderate activities Physical Functioning 0.84 0.17 0.83 0.31
Climb several flights Physical Functioning 0.82 0.17 0.81 0.32
Accomplished less Role Physical 0.81 0.29 0.83 0.41
Limited in kind of 
work
Role Physical 0.80 0.28 0.83 0.39
Pain interferes Bodily Pain 0.72 0.35 0.80 0.45
Health in general General Health 0.68 0.29 0.72 0.43
Energy Vitality 0.56 0.39 0.57 0.53
Social time Social Functioning 0.47 0.56 0.52 0.68
Accomplished less Role Emotional 0.30 0.77 0.37 0.75
Note careful Role Emotional 0.24 0.76 0.32 0.70
Peaceful Mental Health 0.11 0.62 0.19 0.64
Blue/sad Mental Health 0.27 0.67 0.33 0.75
Higher loadings of each item on a factor and higher correlations with a SF-12 component are indicated in bold
1P < 0.01 for all correlations
Table 1: SF-12 item and summary descriptive statistics (N = 1005)
Item description (scale) Mean (SD) 95% CI Median Response frequencies (%)
123456
Moderate activities (PF) 2.64 (0.66) 2.60-2.68 3.00 10.1 15.7 74.2 - - -
Climb several flights (PF) 2.54 (0.72) 2.50–2.59 3.00 13.5 18.5 68.0 - - -
A c c o m p l i s h e d  l e s s  ( R P ) 1 . 8 0  ( 0 . 4 0 ) 1 . 7 7 – 1 . 8 2 2 . 0 0 2 0 . 4 7 9 . 6 ----
L i m i t e d  k i n d  o f  w o r k  ( R P ) 1 . 8 2  ( 0 . 3 9 ) 1 . 7 9 – 1 . 8 4 2 . 0 0 1 8 . 4 8 1 . 6 ----
Pain interferes1 (BP) 4.36 (1.08) 4.29–4.42 5.00 3.0 7.3 7.2 16.2 66.3 -
Health in general1 (GH) 3.24 (1.10) 3.17–3.30 3.00 5.9 19.9 33.2 26.8 14.2
Energy1 (VT) 4.19 (1.31) 4.11–4.28 4.00 2.9 9.7 15.6 24.9 30.9 16.0
Social time (SF) 4.16 (1.15) 4.09–4.23 5.00 3.8 7.7 13.3 19.5 55.7 -
A c c o m p l i s h e d  l e s s  ( R E ) 1 . 8 0  ( 0 . 4 0 ) 1 . 7 7 – 1 . 8 2 2 . 0 0 2 0 . 2 7 9 . 8 ----
N o t e  c a r e f u l  ( R E ) 1 . 8 4  ( 0 . 3 7 ) 1 . 8 2 – 1 . 8 6 2 . 0 0 1 6 . 0 8 4 . 0 ----
Peaceful1 (MH) 3.92 (1.21) 3.84–3.99 4.00 2.3 11.8 20.6 30.4 26.9 8.0
Blue/sad (MH) 4.58 (1.22) 4.50–4.66 5.00 1.6 5.9 9.7 23.5 34.1 25.2
Summary statistics PCS-12 MCS-12
Mean (SD) 49.42 (10.56) 48.91 (9.20)
95% CI 48.77–50.08 48.34–49.48
Median 54.21 51.35
Skewness -1.34 -1.09
Minimum (% floor) 14.01 (0.01) 13.89 (0.01)
Maximum (% ceiling) 66.76 (0.01) 65.39 (0.01)
1 Item recoded so that higher scores correspond to better health.
Abbreviations: PF: Physical Functioning, RP: Role Physical, BP: Bodily Pain, GH: General Health, VT: Vitality, SF: Social Functioning, RE: Role 
Emotional, MH: Mental HealthHealth and Quality of Life Outcomes 2007, 5:55 http://www.hqlo.com/content/5/1/55
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Significant differences were observed within both SF-12
component scores across the distributions of the demo-
graphic and health-related variables (Table 3). Men scored
higher than women and both summary scores were nega-
tively associated with age. The adopted proxy indicators of
socio-economic status (education and employment) were
positively related to HRQOL. Furthermore, being
divorced/widowed, suffering from a clinical condition
and higher health service utilization (physician consulta-
tions and hospital admissions) all correlated negatively
with PCS-12 and MCS-12 summary scores. These differ-
ences were statistically significant (P  < 0.01) and con-
firmed expected relationships in support of the construct
validity of the instrument.
SF-12 summary scores were compared to the respective
SF-36 components and the concordance between them
was noteworthy. Scores were almost identical and, in any
case, differences were never greater than two percentage
points in any of the subgroups on either the PCS-12 or
MCS-12 components, and such a difference would not be
subjectively or clinically meaningful [3,5]. Effect size dif-
ferences between SF-36 and SF-12 scores were generally
small (<0.2), implying that the SF-12 gave similar results
to the SF-36 and support concurrent (criterion) validity of
the Greek version of the instrument.
Significantly lower mean PCS-12 and MCS-12 scores were
observed for respondents reporting specific health prob-
lems, compared to those without (Table 4). It should be
noted that "sleeping disorders" refers to negative
Table 3: Mean (SD) SF-36 and SF-12 summary scores and effect sizes by subgroups
Variable N (%) Physical Component Summary (PCS) Mental Component Summary (MCS)
SF-36 SF-12 Effect* size SF-36 SF-12 Effect* size
Total sample 1005 (100) 50.17 (11.80) 49.42 (10.56) -0.06 47.59 (9.34) 48.91 (9.20) 0.14
Gender
Male 483 (48.1) 51.71 (11.32) 50.49 (10.27) -0.11 48.34 (8.66) 49.90 (8.34) 0.19
Female 522 (51.9) 48.74 (12.06) 48.44 (10.75) -0.02 46.90 (9.88) 47.98 (9.84) 0.11
Age (years)
18–24 115 (11.4) 56.70 (5.14) 55.25 (4.40) -0.28 51.00 (5.77) 52.45 (5.71) 0.25
25–34 185 (18.4) 56.47 (5.12) 54.88 (4.38) -0.31 49.58 (8.07) 51.52 (7.53) 0.24
35–44 180 (17.9) 54.44 (7.27) 53.51 (6.44) -0.13 48.29 (8.29) 50.18 (8.08) 0.23
45–54 151 (15.0) 51.90 (10.11) 51.10 (9.31) -0.08 46.49 (10.00) 47.59 (10.00) 0.11
55–64 150 (15.0) 45.87 (13.07) 45.26 (11.68) -0.05 45.43 (10.77) 47.09 (10.27) 0.15
≥65 224 (22.3) 39.89 (13.28) 40.30 (11.87) 0.03 45.85 (10.25) 46.00 (10.09) 0.01
Education
<9 years 334 (33.2) 43.28 (13.74) 43.29 (12.21) 0.00 45.12 (10.29) 45.89 (10.27) 0.07
9–12 years 422 (42.0) 53.36 (9.30) 52.13 (8.35) -0.13 48.34 (8.84) 49.99 (8.55) 0.19
>12 years 249 (24.8) 54.00 (8.21) 53.08 (7.52) -0.11 49.65 (8.04) 51.12 (7.57) 0.18
Marital status
Single 244 (24.3) 55.34 (7.99) 54.02 (6.94) -0.17 49.78 (7.37) 51.35 (7.18) 0.21
Married 646 (64.3) 49.62 (11.77) 48.84 (10.72) -0.07 47.31 (9.46) 48.71 (9.22) 0.15
Divorced/Widowed 115 (11.4) 42.26 (13.61) 42.97 (11.88) 0.05 44.55 (11.21) 44.85 (11.14) 0.03
Employment
Working 499 (49.7) 54.41 (7.97) 53.31 (7.05) -0.14 48.67 (8.06) 50.39 (7.79) 0.21
Retired 227 (22.6) 40.38 (13.98) 40.52 (12.45) 0.01 46.03 (10.72) 46.39 (10.48) 0.03
House keeping 177 (17.6) 48.13 (11.76) 47.65 (10.43) -0.04 46.36 (10.42) 47.63 (10.59) 0.12
Student 67 (6.6) 55.45 (7.06) 54.10 (6.49) -0.19 50.38 (7.11) 51.72 (6.33) 0.19
Unemployed 35 (3.5) 53.36 (8.94) 51.72 (8.76) -0.18 43.21 (10.96) 45.09 (10.30) 0.17
Chronic Disease (1 or more)
Yes 360 (35.8) 42.45 (13.71) 42.45 (12.29) 0.00 45.07 (10.45) 45.89 (10.46) 0.08
No 645 (64.2) 54.48 (7.78) 53.32 (6.88) -0.15 49.00 (8.33) 50.59 (7.94) 0.19
Physician Visit (past month)
Yes 297 (29.6) 43.05 (13.69) 42.95 (12.54) -0.01 45.55 (10.80) 46.36 (10.61) 0.08
No 702 (69.9) 53.15 (9.43) 52.14 (8.39) -0.11 48.45 (8.51) 49.97 (8.30) 0.18
Hospitalization (past year)
None 880 (87.6) 51.29 (10.97) 50.49 (9.71) -0.07 47.91 (9.03) 49.28 (8.94) 0.15
Once 85 (8.5) 44.29 (14.41) 44.05 (13.12) -0.02 46.13 (10.38) 46.60 (9.65) 0.05
>Once 30 (3.0) 36.83 (12.89) 36.40 (12.25) -0.03 40.41 (11.56) 42.13 (11.25) 0.15
* Negative effect sizes indicate a lower SF-12 summary score compared to the respective SF-36 summary score
1P < 0.01 for all PCS-12 and MCS-12 subgroup differencesHealth and Quality of Life Outcomes 2007, 5:55 http://www.hqlo.com/content/5/1/55
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responses, from the subjects, to duration- and quality-of-
sleep questions, and not to diagnosed insomnia and this
perhaps justifies the high prevalence of this condition in
the sample. Along with hypertension and obesity, these
subgroups contained the largest number of positive
respondents, i.e. people reporting the specific health
problem and this perhaps implies that the score differ-
ences observed in the other disease groups were some-
times insignificant due to the smaller number of people
reporting those particular conditions. In any case, the
results are indicative of the discriminative ability of the
SF-12 since for every health problem, at least one sum-
mary score was significantly lower in the group of positive
respondents.
Subjects indicating a moderate or severe problem on any
of the EQ-5D dimensions had significantly lower (P <
0.001) mean SF-12 component scores compared to sub-
jects reporting no problems, confirming the ability of the
SF-12 to discriminate between different levels of health
(Table 5). The MCS-12 summary scores appeared to dif-
ferentiate better than the PCS-12 ones between the three
levels in each EQ dimension, except for usual activities
where mean scores were quite similar for those reporting
moderate and severe problems. On the other hand, the
PCS-12 summary scores discriminated better between
respondents of the lowest and highest EQ-5D levels
(approximately 20 percentage points or more). It should
be noted that the number of severe problem reporters in
the mobility, self-care and usual activities dimensions was
small and could have affected these particular results.
Convergent and divergent validity of the SF-12 were con-
firmed via the relationships with the EQ-5D (Table 6).
Comparable summary scores and dimensions correlated
better, e.g. PCS-12 with mobility (r = -0.69), usual activi-
ties (r = -0.71) and pain discomfort (r = -0.61) and MCS-
12 with anxiety/depression (r = -0.47), indicating conver-
gent validity. On the other hand, less comparable sum-
mary scores and dimensions correlated weakly, e.g. PCS-
12 and anxiety/depression (r = -0.28) and MCS-12 and
mobility (r = -0.34), supporting divergent validity of the
SF-12. Contrarily, the EQ VAS correlated reasonably well
with both SF-12 summary scores, namely r = 0.68 with
PCS-12 and r = 0.49 with MCS-12.
Discussion
This study reports on the first ever examination of the psy-
chometric properties of the Greek SF-12 and is expected to
add to the growing list of languages and cultures for which
the instrument has been evaluated. Initial evidence was
provided on the construct and concurrent validity of the
instrument, supported by self-reported data on sociode-
mographic and clinical characteristics. This implies that
the SF-12 is potentially suitable for inclusion in large-scale
health surveys in Greece and for cross-cultural quality of
life comparisons, as a valid alternative to the SF-36.
The embedded form of the SF-12, i.e. as a subset of the SF-
36, was used in the present study. It has been demon-
Table 4: Mean (SD) SF-12 summary scores by self-reported 
health problems
SF-12 summary scores
Variable (condition) N (%) PCS-12 MCS-12
Diabetes 62 (6.2) 40.84 (12.60) 44.79 (10.98)
Without 943 (93.8) 49.99 (10.17)*** 49.18 (9.01)**
Hypertension 134 (13.3) 39.35 (12.30) 45.03 (10.61)
Without 871 (86.7) 50.98 (9.36)*** 49.50 (8.81)***
Heart problem 16 (1.6) 34.50 (10.90) 47.81 (11.70)
Without 989 (98.4) 49.67 (10.39)*** 48.92 (9.16)
Asthma 15 (1.5) 45.53 (10.72) 48.73 (9.78)
Without 990 (98.5) 49.48 (10.56)* 48.91 (9.19)
Hip/Knee problem 25 (2.5) 43.38 (10.46) 45.39 (9.37)
Without 980 (97.5) 49.58 (10.53)** 48.50 (9.18)
Depression 24 (2.4) 46.52 (9.97) 40.86 (10.58)
Without 981 (97.6) 49.50 (10.57) 49.10 (9.08)***
Sleeping disorders 254 (25.3) 41.10 (12.40) 42.81 (10.66)
Without 751 (74.7) 52.24 (8.13)*** 50.97 (7.61)***
Obesity (BMI > 30) 185 (18.4) 44.84 (12.39) 45.95 (9.98)
Without 820 (81.6) 50.46 (9.82)*** 49.57 (8.80)***
* P < 0.05, ** P < 0.01, *** P < 0.001
Table 5: Mean (SD) SF-12 summary scores by EQ-5D 
dimensions
SF-12 summary scores
EQ-5D Dimension N (%) PCS-12* MCS-12*
Mobility
No problems 790 (78.6) 53.24 (6.60) 50.52 (7.90)
Moderate problems 210 (20.9) 35.44 (10.57) 43.16 (10.90)
Severe problems 5 (0.5) 33.24 (11.17) 34.53 (13.57)
Self-care
No problems 955 (95.5) 50.38 (9.73) 49.31 (8.84)
Moderate problems 46 (4.6) 31.41 (9.70) 42.03 (11.89)
Severe problems 4 (0.4) 29.43 (7.67) 32.16 (13.95)
Usual activities
No problems 817 (81.3) 53.08 (6.62) 50.69 (7.76)
Moderate problems 173 (17.2) 33.91 (9.70) 41.28 (10.50)
Severe problems 15 (1.5) 29.06 (9.67) 39.58 (14.19)
Pain/discomfort
No problems 669 (66.6) 53.87 (6.53) 51.38 (7.64)
Moderate problems 286 (28.5) 41.85 (11.00) 45.18 (9.42)
Severe problems 50 (5.0) 33.34 (11.55) 37.18 (10.79)
Anxiety/depression
No problems 568 (56.5) 51.78 (8.83) 52.34 (6.88)
Moderate problems 362 (36.0) 47.28 (11.26) 45.73 (8.88)
Severe problems 75 (7.5) 41.95 (13.29) 38.24 (12.05)
* All relationships between EQ-5D dimensions and SF-12 component 
scores were significant (P < 0.001)Health and Quality of Life Outcomes 2007, 5:55 http://www.hqlo.com/content/5/1/55
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strated that both the embedded and stand-alone versions
are similar in terms of item ordering, that factor content
and structure are equivalent [8] and that responses to the
SF-12 items abstracted from the SF-36 are the same as
those obtained from the SF-12 administered alone [31].
Perhaps the unembedded form would have been ideal for
this study in light of timesaving, however, the use of the
embedded form does not pose a threat to the validity of
the results.
The two-factor structure of the instrument and the item-
factor loadings were confirmed using principal compo-
nents analysis, thus ensuring that the conceptual model of
the original US version was satisfactorily replicated.
Hypotheses regarding the correlation of individual item-
component correlations were tested and confirmed,
except for the VT item which appeared to correlate higher
with the PCS-12 than with the MCS-12 score. In general,
this was expected since the VT scale is a general measure
and usually correlates with both components [6]. Further-
more, VT loaded highly on both summary components.
In the cross-cultural context, this particular result has been
observed in studies involving general as well as disease
populations [7,13,32].
No floor or ceiling effects in the SF-12 scores were
observed in this general population sample, indicating
the ability of the instrument to capture a full range of
health states. Correlations between SF-36 and SF-12 sum-
mary scores reached the expected 0.9 standard and the
variability in the PCS-36 explained by the PCS-12 and in
the MCS-36 explained by the MCS-12 was 93.2% and
86.9% respectively. The concordance between PCS-12
and PCS-36 and between MCS-12 and MCS-36 observed
here is in agreement with results from general population
studies in the US [7] and Europe [9] as well as with others
involving patient populations [13,31,33].
The SF-12 summary scores were able to distinguish
between groups of respondents in the expected manner
(known-groups validity) on the basis of gender, age,
socio-economic status, self-reported health problems and
health services utilization (a proxy of HRQOL), providing
evidence of its construct validity. The finding that MCS
scores decreased with increasing age is not consistent with
the majority of the literature that notes that MCS scores
tend to improve with increasing age (as opposed to PCS
scores which generally decline). A possible explanation
for our finding is that 43% and 59% of the 55–64 and >65
age groups respectively reported suffering from multimor-
bidity, i.e. the co-occurrence of two or more chronic con-
ditions [34], and specifically diabetes, hypertension and
heart problems, all of which are clearly associated with
impaired HRQOL in all domains [35,36]. In a recent
Greek study involving elderly diabetic multimorbid
patients, SF-36 subscales hypothetically correlating with
the MCS (i.e. VT, SF, RE and MH), were significantly
reduced [37]. In another SF-36 study involving a Greek
general population, the MCS scores also appeared to
decline with increasing age [24].
In a future study specifically aimed at measuring HRQOL,
it would be interesting to examine the effect of each soci-
odemographic and health-related characteristic since, e.g.
lower scores for divorced/widowed persons may be due to
being older. The same applies for being retired. SF-12
summary scores were compared to SF-36 scores and were
found to be very close, within two percentage points at
most. These differences are small and unlikely to be of
clinical relevance, since it has been suggested that a mini-
mal threshold difference for the SF-36 is around five
points [38]. These results, in conjunction with the small
effect size differences between the SF-36 and SF-12 scores
(<0.2), provide evidence to support the content and con-
current (criterion) validity of the Greek SF-12.
Health conditions, known to be reliable when self-
reported, had an effect on SF-12 summary scores and sig-
nificantly lower mean PCS-12 and MCS-12 scores were
expectedly recorded for respondents reporting diabetes,
hypertension, heart problems, asthma, hip/knee prob-
lems, depression, sleeping disorders or obesity, compared
to those without. Using the EQ-5D as a previously tested
and accepted standard helped to further support validity.
The SF-12 discriminated well between subjects reporting
no problem, a moderate problem or a serious problem for
a given EQ-5D dimension, since indicating a health prob-
lem resulted in significantly (P < 0.001) lower mean SF-12
Table 6: Correlations between SF-12 summary scores and EQ-5D dimensions and VAS
SF-12 summary scores EQ-5D dimensions
Mobility Self-care Usual activities Pain/discomfort Anxiety/depression EQ VAS
PCS-12 -0.69 -0.38 -0.71 -0.61 -0.28 0.68
MCS-12 -0.34 -0.20 -0.40 -0.42 -0.47 0.49
1P < 0.01 for all correlations
Strong correlations (>0.50) indicated in boldHealth and Quality of Life Outcomes 2007, 5:55 http://www.hqlo.com/content/5/1/55
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component scores. However, it should be noted that few
persons reported severe problems in three of the five
domains (i.e. mobility, self-care and usual activities), and
this implies that these results should be dealt with cau-
tiously. Finally, convergent and divergent validity of the
SF-12 were confirmed by the relationships with the EQ-
5D. Comparable summary scores and dimensions corre-
lated higher than less comparable ones, whereas the EQ
VAS correlated reasonably well with both SF-12 summary
scores.
Conclusion
Based on the results from this study, the psychometric
properties of the Greek SF-12 appear to be sound and sug-
gest its potential for measuring health status in large-scale
studies, particularly when overall physical and mental
health are the outcomes of interest instead of the typical
eight-scale profile. Its major advantage stems from its
brevity, which results in fewer burdens for researchers and
respondents. It appears to satisfactorily replicate SF-36
summary scores constituting it an attractive generic instru-
ment to use in clinical practice or research when studying
HRQOL. In this particular study, cross-sectional construct
validity and sensitivity of the Greek SF-12 have been fairly
demonstrated. On the other hand, issues such as test-
retest reliability, longitudinal construct validity and
responsiveness have not been addressed and should be
considered for future studies. This is particularly impor-
tant as health status changes over time and the instrument
must be able to detect these changes, particularly those of
clinical importance.
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